Massachusetts’ top court opened the door for consumers to sue Merck and other brand-name drug makers over injuries blamed on generic forms of their treatments made by other companies.
California’s top court opened the door for consumers to sue Novartis AG and other makers of brand-name pharmaceutical products over injuries blamed on generic versions of the drugs manufactured by other companies.
November 24, 2015By Mark Terry, BioSpace.com Breaking News Staff Now that the Pfizer (PFE)-Allergan (AGN) merger is official, the company and analysts are looking at details about the merged company splitting into two or more companies. This isn’t exactly new thinking. All throughout the three weeks of rumors, the idea that the new mega-company […]
(Reuters Health) – Prescribing generic medicines instead of brand name drugs whenever possible cuts costs, improves patient adherence and improves health outcomes, according to a new recommendation from the American College of Physicians. “Generic medications are cheaper and patients are more likely to get those prescriptions filled,” said Dr. Amir Qaseem of the American College […]
ALEXANDRIA, Va., Aug. 27, 2015 /PRNewswire-USNewswire/ — The Academy of Managed Care Pharmacy (AMCP) is disappointed in the Food and Drug Administration’s (FDA’s) draft guidance and proposed rule that calls for biologics, including reference products and biosimilars, to bear a nonproprietary name with an FDA-designated suffix. For several years, AMCP has been seeking a decision from the […]
Cheaper versions of biologic drugs would be identified by a suffix to distinguish them from their more expensive, branded counterparts under draft guidance issued on Thursday by the U.S. Food and Drug Administration. The FDA said its proposal is designed to prevent inadvertent substitution of non-interchangeable products and to make it easier to monitor and […]